Sunshine and rash: Testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.

Original languageEnglish (US)
Pages (from-to)198-202
Number of pages5
JournalSupportive Cancer Therapy
Volume4
Issue number4
DOIs
StatePublished - Sep 2007

Fingerprint

Sunscreening Agents
Sunlight
Exanthema
Epidermal Growth Factor Receptor
Palliative Care
Placebos

Keywords

  • Prevention
  • Squamous cell carcinoma
  • Ultraviolet light

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

@article{ea459c7f93574d69a356f5c24b3e21b4,
title = "Sunshine and rash: Testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash",
abstract = "Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.",
keywords = "Prevention, Squamous cell carcinoma, Ultraviolet light",
author = "Aminah Jatoi",
year = "2007",
month = "9",
doi = "10.3816/SCT.2007.n.015",
language = "English (US)",
volume = "4",
pages = "198--202",
journal = "Supportive Cancer Therapy",
issn = "1543-2912",
publisher = "Cancer Information Group, LP",
number = "4",

}

TY - JOUR

T1 - Sunshine and rash

T2 - Testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash

AU - Jatoi, Aminah

PY - 2007/9

Y1 - 2007/9

N2 - Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.

AB - Most patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash. To date, no effective palliative therapy has been developed for these rashes. This review describes the rationale behind N05C4, a placebo-controlled trial of sunscreen as an intervention to prevent EGFR inhibitor-related rash.

KW - Prevention

KW - Squamous cell carcinoma

KW - Ultraviolet light

UR - http://www.scopus.com/inward/record.url?scp=35348967015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348967015&partnerID=8YFLogxK

U2 - 10.3816/SCT.2007.n.015

DO - 10.3816/SCT.2007.n.015

M3 - Article

C2 - 18632517

AN - SCOPUS:35348967015

VL - 4

SP - 198

EP - 202

JO - Supportive Cancer Therapy

JF - Supportive Cancer Therapy

SN - 1543-2912

IS - 4

ER -